Osimertinib was not approved by the FDA on November 13, 2015. The drug Tagrisso (osimertinib) received its first FDA approval on November 13, 2015, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a specific epidermal growth factor receptor (EGFR) mutation. [1]
When did Tagrisso (osimertinib) first receive FDA approval?
Tagrisso (osimertinib) was granted FDA approval on November 13, 2015. [1]
What is Tagrisso approved for?
Tagrisso is approved to treat certain types of non-small cell lung cancer (NSCLC). Specifically, it is indicated for patients whose tumors have epidermal growth factor receptor (EGFR) mutations. [1] It was initially approved for metastatic NSCLC with the EGFR T790M mutation and later expanded for first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or EGFR exon 21 L858R mutations. [2]
What kind of EGFR mutations does Tagrisso target?
Tagrisso targets specific EGFR mutations, including the T790M resistance mutation, as well as exon 19 deletions and exon 21 L858R mutations. [2]
Who manufactures Tagrisso?
Tagrisso is manufactured by AstraZeneca. [1]
What are the safety considerations for Tagrisso?
Common side effects of Tagrisso include diarrhea, rash, dry skin, stomatitis, and fatigue. More serious side effects can include interstitial lung disease/pneumonitis, heart problems (QT prolongation), and skin toxicity. [3] Patients are advised to discuss any potential risks and side effects with their healthcare provider.
How does Tagrisso work?
Tagrisso is a tyrosine kinase inhibitor (TKI) that works by targeting and blocking the activity of abnormal EGFR proteins, which drive the growth of certain lung cancers. [4]
When does the patent for osimertinib expire?
Patent information for pharmaceuticals can be complex and subject to change. For detailed and up-to-date information on osimertinib patent expiries, DrugPatentWatch.com is a valuable resource. [5]
What are the alternatives to Tagrisso for EGFR-mutated NSCLC?
Other EGFR inhibitors are available for treating NSCLC with specific EGFR mutations, though the approved indications and resistance mechanisms can differ. These may include gefitinib, erlotinib, and afatinib. [4]
Are there generic versions of osimertinib available?
As of now, generic versions of osimertinib are not widely available. The exclusivity periods granted by patents typically precede the availability of generic alternatives. Information on generic availability can be found through resources like DrugPatentWatch.com. [5]
What is the clinical data supporting Tagrisso's approval?
The initial FDA approval for Tagrisso was based on clinical trials demonstrating its efficacy in patients with T790M-mutated NSCLC. Subsequent approvals for first-line treatment were supported by data showing significant improvements in progression-free survival compared to older EGFR inhibitors. [2]
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-archive
[2] https://www.tagrisso.com/hcp/about-tagrisso/clinical-studies
[3] https://www.tagrisso.com/patient/about-tagrisso/side-effects
[4] https://www.cancer.gov/about-cancer/treatment/drugs/osimertinib
[5] https://drugpatentwatch.com/